Medical device firm Zynex's Q3 revenue misses expectations

Zynex

17/11/2025 22:25

Overview

Zynex Q3 revenue fell 73% yr/yr, missing analyst expectations

Company reported a Q3 net loss of $42.9 mln, impacted by asset impairment charges

Outlook

Zynex exploring strategic alternatives, including capital raising and restructuring

Company enters 30-day grace period for $1.5 mln interest payment

Result Drivers

TRICARE PAYMENT SUSPENSION - Revenue decline attributed to Tricare payment suspension and $2.8 mln revenue reduction during suspension period

CLAIM SUBMISSION CHANGES - Changes to payer claim submissions and review practices led to denials and payment delays, impacting revenue

WORKFORCE REDUCTIONS - Workforce reductions in early 2025 negatively impacted device orders, new patient onboarding, and revenue

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$13.40 mln
$23.02 mln (2 Analysts)
Q3 EPS
-$1.42
Q3 Net Income
-$42.90 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Zynex Inc is $2.85, about 80.1% above its November 14 closing price of $0.57

Press Release: ID:nPn6Ry2tfa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)